MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson’s Disease Reduces the Risk of Polypharmacy: Five-Year Analysis

    M. Hacker, M. Turchan, A. Currie, L. Heusinkveld, S. Millan, T. Davis, F. Phibbs, P. Hedera, P. Konrad, D. Charles (Nashville, TN, USA)

    Objective: To compare the proportion of subjects on polypharmacy after five years in the deep brain stimulation (DBS) in early stage Parkinson’s disease (PD) pilot…
  • 2017 International Congress

    Automated dosing schemes for administration of microtablets of levodopa for Parkinson’s disease, using wearable sensors

    I. Thomas, F. Bergquist, D. Johansson, D. Nyholm, M. Memedi, J. Westin (Falun, Sweden)

    Objective: The aim of this study is to investigate the feasibility of using a dose optimization algorithm for dose individualization of microtables of levodopa. Background:…
  • 2017 International Congress

    Evaluation of rotigotine transdermal patch in combination with low or high dose levodopa in patients with Parkinson’s disease: post-hoc analysis

    E. Dohin, F. Woltering, M. Asgharnejad (Brussels, Belgium)

    Objective: To investigate the value of adding the dopamine agonist (DA) rotigotine (RTG) to low (<400mg/day) or high (≥400mg/day) levodopa (Ldopa) doses in patients with…
  • 2017 International Congress

    ND0701: A new concentrated formulation of Apomorphine for continuous subcutaneous administration – human PK data

    L. Adar, C. Durlach, O. Yacoby Zeevi, D. Fishelovitch, S. Oren (Rehovot, Israel)

    Objective: To evaluate the PK and relative bioavailability of ND0701, a subcutaneously (SC) infused apomorphine-base product candidate, and a commercial apomorphine-HCl product. The secondary objective…
  • 2017 International Congress

    Improvement in attention/memory domains in advanced Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel is associated with better quality of life

    D. Standaert, R. Rodriguez, J. Slevin, M. Lobatz, C. Hall, M. Facheris, J. Benesh, S. Dubow (Birmingham, AL, USA)

    Objective: To evaluate the relationship between non-motor symptom (NMS) severity, quality of life (QoL), and activities of daily living (ADL) in advanced Parkinson’s disease (PD)…
  • 2017 International Congress

    The effect of early STN-DBS in PD patients on axial symptoms: a 2-year randomized controlled trial (EARLYSTIM-Gait analysis)

    M. Barbe, L. Tonder, F. Sixel-Döring, B. Debû, L. Timmermann, A. Schnitzler, C. Schade-Brittinger, J. Rau, P. Krack, J.-L. Houeto, M. Schüpbach, G. Deuschl (Cologne, Germany)

    Objective: This study assesses the effect of STN-DBS in early PD patients on axial symptoms compared to BMT. Background: In well-selected candidates, STN-DBS offers symptom…
  • 2017 International Congress

    Efficacy and Safety of Therapeutic Interventions to Treat Motor Symptoms in Late Stage Parkinson’s Disease: A Systematic Review

    M. Coelho, K. Destri, M. Fabbri, A. Schrag, J. Ferreira, b.C. Consortium (Lisbon, Portugal)

    Objective: Evaluate the efficacy and safety of therapeutic interventions to treat the motor symptoms in late stage PD. Background: PD patients in late stage are…
  • 2017 International Congress

    Understanding neural activation in semantic fluency in Parkinson’s disease with mild cognitive impairment

    J.H. Julia, K. McMahon, D. Copland, G. Byrne, A. Toft, L. Mithcell, J. O'Sullivan, N. Dissanayaka (Herston, Australia)

    Objective:  To identify neural mechanisms relating to semantic fluency deficits in PD-MCI and to establish possible neuroimaging markers for Parkinson’s disease (PD) with dementia.  Background:…
  • 2017 International Congress

    Morphometric changes in Parkinson’s disease manifesting freezing of gait

    S. Pietracupa, A. Suppa, N. Upadhyay, A. Zampogna, F. Di Biasio, G. Grillea, N. Modugno, G. Fabbrini, A. Berardelli, P. Pantano (Pozzilli, Italy)

    Objective: To study structural Gray Matter (GM) and White Matter (WM) changes in Parkinson’s Disease (PD) patients with Freezing of Gait (FOG). Background: FOG is…
  • 2017 International Congress

    The combination of the MIBG myocardial scintigraphy and DATSPECT contributes to the diagnosis of PD and other related disorders.

    S. Tada, H. Ohtsubo, Y. Yamanishi, N. Miyaue, R. Ando, H. Yabe, N. Nishikawa, M. Nagai, M. Miyagawa, M. Nomoto (Ehime, Japan)

    Objective: To evaluate MIBG and DAT SPECT for the diagnosis of Parkinson’s disease (PD) and related disorders, we performed 123I-meta-iodobenzylguanzylguanidine (MIBG) myocardial scintigraphy and (123I)-FP-CIT…
  • « Previous Page
  • 1
  • …
  • 46
  • 47
  • 48
  • 49
  • 50
  • …
  • 155
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley